(WO/1999/051243) THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY
- Biblio. Data
- Description
- Claims
- National Phase
- Notices
- Documents
| Latest bibliographic data on file with the International Bureau
| |||||||||||||||||||
| |||||||||||||||||||
| IPC: | A61K 38/09 (2006.01) | ||||||||||||||||||
| Applicant: | JENAPHARM GMBH & CO. KG [DE/DE]; Otto-Schott-Strasse 15, D-07745 Jena (DE). | ||||||||||||||||||
| Inventors: | WILDT, Ludwig; (DE). NEUWINGER, Joachim; (DE). LICHT, Peter; (DE). DITTRICH, Ralph; (DE). OETTEL, Michael; (DE). HUMMEL, Wolfgang; (DE). | ||||||||||||||||||
| Agent: | CRAMER, Eva-Maria; Jenapharm GmbH & Co. KG, Otto-Schott-Strasse 15, D-07745 Jena (DE). | ||||||||||||||||||
| Priority Data: |
| ||||||||||||||||||
| Title: |
(EN) THE USE OF ESTRADIOL DERIVATIVES FOR TREATING SIDE-EFFECTS DURING AND/OR AFTER GnRHa THERAPY (DE) PHARMAZEUTISCHE PRÄPARATE ZUR THERAPIE VON NEBENWIRKUNGEN WÄHREND UND/ODER NACH EINER GnRHa-THERAPIE | ||||||||||||||||||
| Abstract: |
(EN) The invention relates to the use of at least one active agent from the following group: 17$g(a)-estradiol, its chemically modified derivatives and chemically modified derivatives of 17$g(b)-estradiol or estriol; for producing pharmaceutical preparations for treating side effects such as hot flushes during and/or after a treatment with analogs or antagonists of the gonadotropin-releasing hormone (GnRHa-therapy). Said pharmaceutical preparations can be produced in oral and parenteral, including topical, rectal, sub-cutaneous, intravenous, intramuscular, intraperitoneal, intranasal, intravaginal, intrabuccal or sub-lingual forms of administration. (DE) Die vorliegende Erfindung betrifft die Verwendung von mindestens einem Wirkstoff aus der Gruppe 17$g(a)-Estradiol, dessen chemisch modifizierte Derivate, chemisch modifizierte Derivate des 17$g(b)-Estradiol oder des Estriol zur Herstellung pharmazeutischer Präparate zur Therapie von Nebenwirkungen, wie Hitzewallungen, während und/oder nach einer Behandlung mit Analoga oder Antagonisten des Gonadotropin-Releasinghormons (GnRHa-Therapie). Die pharmazeutischen Präparate können als orale und parenterale, incl. als topische, rektale, subcutane, intravenöse, intramuskuläre, intraperitoneale, intranasale, intravaginale, intrabukkale oder sublinguale Applikationsform vorliegen. | ||||||||||||||||||
| Designated States: |
AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW. African Regional Intellectual Property Org. (ARIPO) (GH, GM, KE, LS, MW, SD, SZ, UG, ZW) Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM) European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE) African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). | ||||||||||||||||||
| Publication Language: | German (DE) |
| Filing Language: | German (DE) |

